medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2018, Number 3

Next >>

Rev Mex Oftalmol 2018; 92 (3)

Corneal epitheliopathy due to sensitive impairment: Neurotrophic keratopathy

Babayán-Sosa A, Baca-Lozada O

Language: Spanish
References: 28
Page: 117-122
PDF size: 101.27 Kb.


ABSTRACT

Neurotrophic keratitis is a degenerative disease characterized by corneal sensitivity reduction, spontaneous epithelium breakdown, and impairment of corneal healing. Several causes of neurotrophic keratitis, including herpetic keratitis, diabetes, trauma and ophthalmic and neurosurgical procedures, share the common mechanism of trigeminal damage. Diagnosis requires accurate investigation of clinical ocular and systemic history, complete eye examination, and assessment of corneal sensitivity. Neurotrophic keratitis can be classified according to severity of corneal damage, superficial punctate keratitis (stage 1), persistent epithelial defect (stage 2), and perforation and melting (stage 3). Management should be based on clinical severity, and aimed at promoting corneal healing and preventing progression of the disease to stromal melting and perforation. Currently, no specific medical treatment exists, and surgical approaches, such as amniotic membrane transplantation and conjunctival flap, are effective in preserving eye integrity, without ameliorating corneal sensitivity or visual function.


REFERENCES

  1. Mackie IA. Neuroparalytic keratitis. En: Fraunfelder F, Roy FH, eds. Current ocular therapy. 4.a ed. Filadelfia; 1995. p. 506-8.

  2. Cobo LM. Corneal complications of herpes zoster ophthalmicus. Prevention and treatment. Cornea. 1988;7(1):50-6.

  3. Rosenwasser GO, Holland S, Pflugfelder SC, Lugo M, Heidemann DG, Culbertson WW, et al. Topical anesthetics abuse. Ophthalmology. 1990;97(8):967-72.

  4. Varga JH, Subinfeld RS, Wolf TC, Stutzman RD, Peele KA, Clifford WS, et al. Topical anesthetic abuse ring keratitis: Report of four cases. Cornea. 1997;16(4):424-9.

  5. Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. Br J Ophthalmol. 1990;74(7):409-12.

  6. Szerenyi K, Sorken K, Garbus JJ, Lee M, McDonnell PJ. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol. 1994;118(3):312-5.

  7. Hyndiuk RA, Kazarian EL, Schultz RO, Seideman S. Neurotrophic corneal ulcers in diabetes mellitus. Arch Ophthalmol. 1977;95(12):2193-6.

  8. Karacorlu MA, Cakiner T, Saylan T. Corneal sensitivity and correlations between decreased sensitivity and anterior segment pathology in ocular leprosy. Br J Ophthalmol. 1991;75(2):117-9.

  9. Foster CS. Corneal Manifestations of Neurologic Diseases. En: Smolin G, Thoft RA. The Cornea. 3.a ed. Boston: Little, Brown and Company; 1994.

  10. Cavanagh HD, Colley AM. The molecular basis of neurotrophic keratitis. Acta Ophthalmol Suppl. 1989;192:115-34.

  11. Kingsley RE, Marffurt CF. Topical substance P and corneal epithelia wound closure in the rabbit. Invest Ophthalmol Vis Sci. 1997;38(2):388-95.

  12. Chikama T, Fukuda K, Morishige N, Nishida T. Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin growth factor 1. Lancet. 1998;351(9118):1783-4.

  13. Labetoulle M, Auquier P, Conrad H, Crochard A, Daniloski M, Bouée S, et al. Incidence of herpes simplex virus keratitis in France. Ophthalmology. 2005;112(5):888-95.

  14. Hamrah P, Cruzat A, Dastjerdi MH, Zheng L, Shahatit BM, Bayhan HA, et al. Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology. 2010;117(10):1930-6.

  15. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44 Suppl 1:S1-26.

  16. Bhatti MT, Patel R. Neuro-ophthalmic considerations in trigeminal neuralgia and its surgical treatment. Curr Opin Ophthalmol. 2005;16(6):334-40.

  17. Belmonte C, Acosta MC, Schmelz M, Gallar J. Measurement of corneal sensitivity to mechanical and chemical stimulation with a CO2 esthesiometer. Invest Ophthalmol Vis Sci. 1999;40(2):513-9.

  18. Heigle TJ, Pukfelder SC. Aqueous tear production in patients with neurotrophic keratitis. Cornea. 1996;15(2):135-8.

  19. Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clini Ophthalmol. 2014;8:571-9.

  20. Sacchetti M, Lambiase A, Cortes M, Sgrulletta R, Bonini S, Merlo D, et al. Clinical and cytological findings in limbal stem cell deficiency. Graefes Arch Clin Exp Ophthalmol. 2005;243(9):870-6.

  21. Grey F, Carley F, Biswas S, Tromans C. Scleral contact lens management of bilateral exposure and neurotrophic keratopathy. Cont Lens Anterior Eye. 2012;35(6):288-91.

  22. Lambiase A, Rama P, Aloe L, Bonini S. Management of neurotrophic keratopathy. Curr Opin Ophthalmol. 1999;10(4):270-6.

  23. Kirkness CM, Adams GGW, Dilly PN, Lee JP. Botulinum toxin A-induced protective ptosis in corneal disease. Ophthalmology. 1988;95(4):473-80.

  24. Khodadoust A, Quinter AP. Microsurgical approach to the conjunctival flap. Arch Ophthalmol. 2003;121(8):1189-93.

  25. Khokhar S, Natung T, Sony P, Sharma N, Agarwal N, Vajpayee RB. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea. 2005;24(6):654-60.

  26. Jhanji V, Young AL, Mehta JS, Sharma N, Agarwal T, Vajpayee RB. Management of corneal perforation. Surv Ophthalmol. 2011;56(6):522-38.

  27. Reed JW, Joyner SJ, Knauer WJ 3rd. Penetrating keratoplasty for herpes zoster keratopathy. Am J Ophthalmol. 1989;107(3):257-61.

  28. Lambiase A, Sacchetti M, Bonini S. Nerve growth factor therapy for corneal disease. Curr Opin Ophthalmol. 2012;23(4):296-302.




2020     |     www.medigraphic.com